Position
Fidelity in C4 Therapeutics, Inc.
Back to the book · All holders of CCCC
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $555.6K$2.63 → $4.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 254.4K | $485.9K | — | — | — | 0.0% |
| Q1 2026 | 272.4K | $716.3K | $2.63 | $183.2K | $47.2K | 0.0% |
| Q2 2026 | 894.1K | $4.18M | $4.67 | $555.6K | $2.9M | 0.0% |